The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial.
 
John Mascarenhas
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Disc Medicine; Galecto; Geron; GlaxoSmithKline; Incyte; Karyopharm Therapeutics; Keros Therapeutics; Merck; MorphoSys; MorphoSys; Novartis; Pharmaessentia; Roche/Genentech; SOBI; Sumitomo Pharma Oncology
Research Funding - Abbvie (Inst); Celgene/Bristol-Myers Squibb (Inst); Disc Medicine; Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); MorphoSys; Novartis (Inst); Pharmaessentia (Inst); SOBI
 
Haris Ali
Consulting or Advisory Role - GlaxoSmithKline; Novartis; PharmaEssentia; SOBI
Speakers' Bureau - Incyte
Research Funding - Incyte
 
Haifa Al-Ali
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; Bristol-Myers Squibb; Geron; GlaxoSmithKline; MSD; Novartis; Otsuka; Stemline Therapeutics
Research Funding - Bristol-Myers Squibb; Incyte
 
Jose Valentin Garcia-Gutierrez
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Menarini; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Menarini; Novartis; Pfizer; Takeda
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Menarini; Novartis; Pfizer; Takeda
 
Sebastian Grosicki
No Relationships to Disclose
 
Zhanet Grudeva
Honoraria - Johnson & Johnson/Janssen; Novartis; Roche; SERVIER; SOBI; Swixx BioPharma; Takeda
Consulting or Advisory Role - Johnson & Johnson/Janssen; Novartis; Roche
Speakers' Bureau - Johnson & Johnson/Janssen; SERVIER; Swixx BioPharma; Takeda
Travel, Accommodations, Expenses - Takeda
 
Claire Harrison
Honoraria - AOP Orphan Pharmaceuticals; GlaxoSmithKline; Incyte; Johnson & Johnson; Karyopharm Therapeutics; Mennari; MorphoSys; Novartis; Stemline Therapeutics
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; GlaxoSmithKline; Incyte; Johnson & Johnson; Karyopharm Therapeutics; Mennari; MorphoSys; Novartis; Opna Bio; pharma&; Stemline Therapeutics
Speakers' Bureau - AOP Orphan Pharmaceuticals; GlaxoSmithKline; Incyte; Johnson & Johnson; Karyopharm Therapeutics; MorphoSys; Novartis; Stemline Therapeutics
Research Funding - GlaxoSmithKline; Novartis
Travel, Accommodations, Expenses - Novartis
 
Jushik Hong
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; PharmaEssentia
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; PharmaEssentia
Research Funding - Boryung; PharmaEssentia; Samyang Biopharm USA
 
Hsin-An Hou
No Relationships to Disclose
 
Michal Kwiatek
Stock and Other Ownership Interests - Aidport; Badania.pl; In-Vivo Clinical Trials Site; Vendozi
Research Funding - Abbvie; ADC Therapeutics; Astellas Pharma; BeiGene; Bristol-Myers Squibb/Pfizer; Genmab; Geron; Ipsen; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Lilly; Nurix; Regeneron
 
Michael Loschi
Consulting or Advisory Role - Astellas Pharma; Gilead Sciences; GlaxoSmithKline; iqone; MaaT Pharma; MaaT Pharma; Novartis
Research Funding - Janssen
Patents, Royalties, Other Intellectual Property - gilteritinib immunological effects
Travel, Accommodations, Expenses - MSD; Novartis/Pfizer
 
Francesco Passamonti
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Kartos Therapeutics; Karyopharm Therapeutics; Menarini Group; Novartis; Roche; Sumitomo Pharma Oncology; Takeda
Speakers' Bureau - AOP Orphan Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Menarini Group; Novartis
Travel, Accommodations, Expenses - Abbvie; GlaxoSmithKline; Novartis
 
Andrea Patriarca
Honoraria - Alexion Pharmaceuticals; Bristol-Myers Squibb; Incyte; Novartis; Pfizer; Recordati; Sanofi; SOBI; Takeda
 
Nikolai Podoltsev
Consulting or Advisory Role - Abbvie; Amgen; Cycle Pharmaceuticals; Incyte; Karyopharm Therapeutics; Novartis; PhramaEssentia; Sobi; Syndax; Takeda
Research Funding - AI Therapeutics (Inst); Aptos Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Jazz Pharmaceuticals (Inst); Kartos Therapeutics (Inst); Karyophram Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaEssentia (Inst); Protagonist Therapeutics (Inst); Samus Therapeutics (Inst); Sunesis Pharmaceuticals (Inst)
Other Relationship - Cogent Biosciences
 
Raajit Rampal
Honoraria - Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Disc Medicine; Galecto; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia; Promedior; SERVIER; Sierra Oncology; Stemline Therapeutics; Sunimoto Dainippon; Zentalis
Research Funding - Constellation Pharmaceuticals; Ryvu Therapeutics; Stemline Therapeutics; Zentalis
Travel, Accommodations, Expenses - Incyte; Sierra Oncology
 
Srinivas Tantravahi
Honoraria - Abbvie; Gentech; GlaxoSmithKline; Karyopharm Therapeutics; MorphoSys; Novartis
Consulting or Advisory Role - Abbvie; Gentech; GlaxoSmithKline; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Karyopharm Therapeutics
 
Laura Urian
No Relationships to Disclose
 
Reshma Rangwala
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Genmab
 
Pankit Vachhani
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; Cogent Biosciences; Disc Medicine; Genentech/Roche; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Merck; Merck; MorphoSys; Novartis; Novartis; Pfizer; Pharmaessentia; SERVIER; SOBI; Stemline Therapeutics; Stemline Therapeutics; Takeda
Speakers' Bureau - Blueprint Medicines; Incyte
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Board member: Alabama Cancer Congress
 
Prithviraj Bose
Honoraria - Incyte; Novartis; Pharmaessentia
Consulting or Advisory Role - Blueprint Medicines; BMS; Cogent Biosciences; Deciphera; Disc Medicine; Geron; GlaxoSmithKline; Incyte; Ionis Pharmaceuticals; Karyopharm Therapeutics; Merck; Novartis; Pharmaessentia; Raythera; SOBI; Sumitomo Dainippon Pharma Oncology/BBI; Takeda
Research Funding - Ajax (Inst); Blueprint Medicines (Inst); BMS (Inst); Cogent Biosciences (Inst); Disc Medicine (Inst); Geron (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); MorphoSys (Inst); Sumitomo Pharma Oncology (Inst); Telios (Inst)